WuXi AppTec (603259) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
24 Mar, 2026Executive summary
Achieved record revenue and adjusted non-IFRS net profit in 2025, with revenue up 21.4% and adjusted net profit up 41.3% year-over-year, surpassing full-year guidance.
Backlog for continuing operations reached RMB 58 billion, up 28.8% year-over-year, reflecting robust customer demand and capacity expansion.
Revenue streams diversified across regions, with 72% from the US, 13% from China, and 11% from Europe.
Achieved top ESG ratings, including MSCI AAA, CDP A, EcoVadis Gold, and inclusion in S&P Global Sustainability Yearbook, with validated near-term GHG reduction targets.
Maintained zero critical findings in 741 quality audits and 60 information security audits, with all main sites ISO/IEC 27001 certified.
Financial highlights
Total revenue reached RMB 45.46 billion; continuing operations revenue grew 21.4% year-over-year to RMB 43.42 billion.
Adjusted non-IFRS net profit rose 41.3% year-over-year to RMB 14.96 billion, with margin improvement to 32.9%.
Adjusted non-IFRS gross profit margin expanded 6.6 percentage points to 48.2%.
Adjusted operating cash flow hit RMB 16.67 billion, up 39.1% year-over-year.
Net profit attributable to owners surged 102.6% to RMB 19.15 billion; diluted EPS more than doubled to RMB 6.61.
Outlook and guidance
2026 revenue guidance: RMB 51.3–53 billion, with continuing operations revenue expected to grow 18–22% year-over-year.
CapEx for 2026 projected at RMB 6.5–7.5 billion; adjusted free cash flow expected at RMB 10.5–11.5 billion.
Board proposes record cash dividend of RMB 5.71 billion for 2026, maintaining a 30% payout ratio.
H share incentive trust plan tied to revenue targets, with no dilution to existing shareholders and share grants to attract and retain top talent.
Latest events from WuXi AppTec
- Integrated CRDMO model, innovation, and ESG drive strong growth and resilience in 2024.603259
43rd Annual J.P. Morgan Healthcare Conference 20253 Feb 2026 - Net profit more than doubled on strong CRDMO growth, margin gains, and asset sale gains.603259
H1 20253 Feb 2026 - Record 2025 results, global expansion, and innovation drive continued growth and sustainability.603259
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - H1 2024 revenue fell, but Q2 rebounded and TIDES grew 57.2%, with strong full-year guidance.603259
H1 202429 Dec 2025 - Q3 revenue rose sequentially, with TIDES growth and robust backlog despite profit decline.603259
Q3 202429 Dec 2025 - Record Q4 and strong 2024 set stage for double-digit growth in 2025.603259
H2 202429 Dec 2025 - Net profit jumped 89% on 21% revenue growth, led by Chemistry and TIDES segments.603259
Q1 202529 Dec 2025 - Record profit and revenue growth, raised guidance, and global expansion fueled by CRDMO strength.603259
Q3 202529 Dec 2025